Precision Oncology Billing: Mastering J-Codes, Infusion Sequencing & Multimodal Cancer Care Reimbursement
Eliminate revenue leakage on high-cost chemotherapy regimens, immunotherapies, and clinical trial pathways. Mednexa deploys certified AAPC hematology-oncology coders to capture every buy-and-bill dollar while preventing payer pre-auth clawbacks.
Oncology Drug & Infusion Live Stream
Synchronized with Epic Beacon & OncoEMR feeds
Specialized Infusion & Multimodal Oncology Nuances
Oncology practices leak up to 28% of drug margin due to inaccurate hierarchy sequencing, unbilled wastage, and missing diagnostic biomarker associations. We protect every phase.
Chemotherapy Infusion Sequencing
Strict multi-agent hierarchy management: initial hour vs. subsequent hours vs. concurrent infusion. We stop commercial payers from automatically reclassifying your primary antineoplastic agents to lower-reimbursing therapeutic injections.
J-Code & Biosimilar Wastage Auditing
Single-dose vial discards represent massive uncaptured cash flow. We systematically align electronic health record log files with CMS JW/JZ modifier directives, preserving your ASP+6% buy-and-bill margins while maintaining rigorous audit readiness.
Oral Oncolytics & Specialty Pharmacy Clearances
Rapid authorization execution for targeted therapies including PARP inhibitors, TKIs, and CDK4/6 inhibitors. We connect patients with non-profit copay foundations and manufacturer assistance funds, preventing treatment abandonment.
Radiation Oncology & Stereotactic Radiosurgery
End-to-end coding capture for complex IMRT, IGRT, SRS, and SBRT courses. We guarantee that radiation dosimetry calculations, multi-leaf collimator (MLC) simulations, and medical physicist review dates match clinical delivery timelines perfectly.
The 4-Stage Mednexa Oncology Protocol
Engineered to protect clinical workflow while systematically removing payment roadblocks from patient intake to secondary AR settlement.
Pre-Infusion Clearance
Verification of staging, biomarker panels (EGFR, ALK, PD-L1, HER2), and payer-specific NCD/LCD limits before any oncology infusion chair is reserved.
AAPC Abstracting
Dual-certified hematology/oncology coders abstract regimen records, managing hydration bundling and applying Medicare Q0/Q1 clinical trial modifier flags.
Chemo Rule Scrubber
Automated algorithmic screening cross-references patient body surface area (BSA) and renal dosing thresholds against FDA labels and quarterly ASP pricing tables.
Appeals Liquidation
Immediate 48-hour turnarounds on commercial medical necessity and off-label questions, backed by peer-reviewed oncology literature and indexed NCCN compendia.
Oncology Infusion Drug Margin Calculator
See what standard billing departments miss on biosimilars, high-cost immunotherapy, and discarded single-dose units. Slide to match your practice's monthly infusion metrics.
Net positive cash flow directly back to practice operational accounts within 90 days of transition.
In-House Billing vs. Mednexa Dedicated Oncology Unit
Generalist billers struggle with the sheer velocity of quarterly ASP changes, intricate chemo regimens, and payer policy nuances. Here is the operational reality.
| Clinical Financial Metric | In-House General RCM | Mednexa Dedicated Unit | Financial Impact |
|---|---|---|---|
| J-Code Wastage Logging (JW / JZ) | close Frequently omitted; write-offs > $45K/yr | check_circle 100% single-dose vial capture | Preserves ASP+6% buy-and-bill |
| Prior Authorization Timelines | close 5–10 Business days; delayed chair slots | check_circle Under 24 hours with biomarker matching | Zero delayed chemo infusions |
| Average Days in A/R | 48.6 Days (Industry Benchmark) | 17.4 Days | 64% Accelerated Cash Flow |
| Staffing & Coder Turnover | close 32% annual turnover in oncology coders | check_circle Dedicated pods with 0% practice disruption | Eliminates onboarding overhead |
| Biologic Denials Appeal Rate | 42% appeal abandonment | check_circle 94.7% successful recovery | Recovers $300k+ in unappealed drugs |
“Mednexa recovered $385,000 in unbilled biosimilar wastage and slashed our infusion claim denials to under 2% in the first 60 days.”
Prior to Mednexa, the practice experienced recurrent pre-authorization clawbacks on combination immunotherapies and faced unpredictable cash flow. Within two months of transition, chair throughput stabilized, clean claim velocity reached 99.4%, and Days in A/R plummeted from 54 to 16.2.
Direct EHR & Oncology Information System (OIS) Integration
Native bidirectional connection—no clunky manual exports or duplicate clinical documentation.
Request Your Confidential Oncology Billing & J-Code Margin Audit
Our Senior Oncology Coding Auditor will review a 30-day anonymized claim sample to pinpoint unbilled JW wastage, hydration bundling errors, and off-label denial vulnerabilities.